Yantai Dongcheng Biochemicals (002675.SZ): Jilin Changchun Nuclear Medicine Production Center is put into operation.
Dongcheng Pharmaceutical Industry (002675.SZ) announced that recently, the company received a notification from its wholly-owned subsidiary, Nanjing Jiangyuan Andyco Electronics Research and Development Co., Ltd. (hereinafter referred to as "Andyco"), informing them that they have received the "Radioactive Drug Production License" issued by the Jiangsu Provincial Drug Administration. This license allows the establishment of a new nuclear medicine production center in Changchun, Jilin. The approval of this review marks the completion of the requirements for the production of nuclear medicine at Andyco's Changchun nuclear medicine production center, and Andyco will establish a new nuclear medicine production center. The operation of the nuclear medicine production center will help Andyco expand its market, increase sales revenue, and further improve the national layout of nuclear medicine network construction.
Yantai Dongcheng Biochemicals (002675.SZ) announced that recently, the company received a notification from its fully-owned subsidiary, Nanjing Jiangyuan Andi Kezheng Electronic Research and Development Co., Ltd. (referred to as "Andike"), informing them that they have received a "Radioactive Drug Production License" issued by the Jiangsu Provincial Drug Administration, adding a new production center in Changchun, Jilin. The approval of this review indicates that Andike's Changchun Nuclear Medicine Production Center has met the production requirements and will add a new nuclear medicine production center. The operation of the nuclear medicine production center will benefit Andike in expanding market and increasing sales revenue, further improving the national network layout of nuclear medicine.
Related Articles
From the frenzy on the dark market to the hard work on entering the main market: CREALITY (03388) is holding its ground in the horizontal market.
Hong Kong student dormitory operator Student Living EduVation (SDLV.US) raises fundraising target to $31 million IPO price $4-6 per share.
One picture understanding the Hong Kong Stock Exchange IPO of LB Pharmaceuticals (09637)
From the frenzy on the dark market to the hard work on entering the main market: CREALITY (03388) is holding its ground in the horizontal market.
Hong Kong student dormitory operator Student Living EduVation (SDLV.US) raises fundraising target to $31 million IPO price $4-6 per share.
One picture understanding the Hong Kong Stock Exchange IPO of LB Pharmaceuticals (09637)
RECOMMEND
